Dr. Mooney talks about the Symphony device’s testing in hospital settings, the prospects for FDA as well as European clearance, and the choices and strategies made to bring the Symphony to market.
More videos with Dr. Mooney:
Patrick Mooney, MD, is the chairman and CEO of Echo Therapeutics and a surgeon by training. He did his surgical residency at Thomas Jefferson University Hospital in Philadelphia after which he left medicine and began working on Wall Street as a securities analyst covering biotechnology companies. He later left Wall Street to run another biotechnology company, and then joined Echo Therapeutics in 2007.
Echo uses a technology that came out of Dr. Robert Langer’s lab at MIT. Dr. Langer invented a device which permeates the skin without needing a needle to penetrate the protective barrier formed by the skin. The device creates a portal into the body to deliver drugs topically or extract analytes, and Echo used this system to create a glucose biosensor, the Symphony tCGM System, to read continuously without the use of a needle.